Lacerta Therapeutics
Megha Mahabole, MS, CTBS has over 10 years of experience in the biotechnology and pharmaceutical industry. Megha is currently working at Lacerta Therapeutics as a Senior Scientist, where they started in July 2022. Prior to this, Megha worked at TissueTech, Inc for 7 years. At TissueTech, they held various roles including Lab Manager, Biochemical Research Scientist, and Sr. Research and Product Development Specialist. Their responsibilities in these roles included managing the laboratory, conducting biochemical research, and developing new products. Before joining TissueTech, Megha worked at Tissue-Tech Inc from 2012 to 2014 as a Research and Product Development Specialist, where they focused on product development, cell-based assays, and standardizing protein isolation techniques. Megha also worked as a Laboratory and Product Development Technician at Tissue-Tech Inc from 2012 to 2013, conducting research on human adipose mesenchymal stem cells and providing lab support to the Ocular Surface Center. Prior to their time at Tissue-Tech, Megha worked as a Research Assistant at Florida Institute of Technology and as an Intern at The Scripps Research Institute and Piramal LifeSciences Limited. In these roles, they conducted research on fertilization and embryonic development in starfish, studied the anti-inflammatory properties of bone marrow mesenchymal stem cells, and performed in vitro compound screening for potential anti-inflammatory drug development. Overall, Megha has a strong background in research, product development, and laboratory management in the biotechnology and pharmaceutical field.
Megha Mahabole has a strong educational background in biotechnology. Megha obtained their Bachelor of Technology degree in Biotechnology from Padmashree Dr D. Y. Patil Vidyapeeth, completing their studies from 2005 to 2009. Following this, Megha pursued a Master's degree in Biotechnology from Florida Institute of Technology, where they attended from 2010 to 2011.
In addition to their formal education, Megha Mahabole has also obtained certifications to enhance their expertise. In December 2017, they obtained the CTBS certification from the American Association of Tissue Banks. This certification demonstrates their knowledge and proficiency in tissue banking.
Furthermore, Megha holds an edX Verified Certificate for Making Biologic Medicines for Patients: The Principles of Biopharmaceutical Manufacturing. However, the specific dates of obtaining this certificate are not provided.
This person is not in any offices
Lacerta Therapeutics
Lacerta Therapeutics is a clinical stage gene therapy company using a constellation of proprietary adeno-associated virus (AAV) vector technologies to develop treatments for central nervous system and lysosomal storage diseases. With unmatched scientific expertise and depth in the development, production, and application of AAV vectors, LacertaTherapeutics is advancing its clinical programs using its proprietary capsid variants and scalable vector manufacturing platform. The experience and accomplishments of the Lacerta Therapeutics founders are unsurpassed in AAV gene therapy. In addition to world-class basic AAV vector development and gene therapy clinical trial expertise, our team brings to bear individuals with novel insight into developing novel, targeted neurological and lysosomal storage disease treatments.